NBP NovaBridge Biosciences
1.370USD-2.14%Mkt Cap: 158.92M $P/E: —1d ago
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
NovaBridge Biosciences (NBP) (H1 2026) Earnings Call Highlights: Strong Cash Position and ... NovaBridge Biosciences (NBP) reports a debt-free balance sheet with $216 million in cash, advancing its lead asset givastomig toward a potential Phase 3 launch in Q4 2026. | ||
NovaBridge Biosciences Q2 2026 Earnings Call Summary Moby summary of NovaBridge Biosciences's Q2 2026 earnings call | ||